Respiratory vaccines specialist Vicebio Ltd. is to be acquired by Sanofi SA in a $1.6 billion deal, of which $1.15 billion will be paid up front. The acquisition rests on an ongoing phase I trial of the lead asset, VXB-241, a bivalent vaccine that is intended to provide protection against both respiratory syncytial virus and metapneumovirus. The interim analysis of the study showed a favorable safety and tolerability profile in adults, ages 60 and older, and validated the underlying vaccine technology, which is applicable to a wide range of respiratory viruses.
We all look different to HIV, a virus that destroys the immune system. The defensive cells record every interaction with foreign agents, infections from viruses and bacteria, but also with mechanisms occurring within the body, such as microbiome metabolism, the effects of aging, or the development of diseases. At a preconference session at the 13th IAS Conference on HIV Science (IAS 2025), scientists explained the interactions of different microorganisms with HIV.
The fate of IL-33-targeting astegolimab will be determined by talks with regulators, after Roche AG’s Genentech unit rolled out mixed results from a pair of studies testing the compound vs. placebo on top of standard-of-care (SOC) maintenance therapy in subjects with moderate to very severe chronic obstructive pulmonary disease (COPD).
Acute respiratory distress syndrome (ARDS) is a life-threatening pulmonary condition marked by intense inflammation, alveolar damage and fluid accumulation in the lungs, often leading to respiratory failure. In a study recently published in Translational Research, researchers aimed to develop a more physiologically relevant model by combining two major ARDS contributors: gastric acid aspiration and ventilator-induced lung injury.
Chronic obstructive pulmonary disease (COPD) is a respiratory disease characterized by chronic inflammation and structural damage to the alveoli, with irreversible declined lung function. M1 pro-inflammatory macrophages mainly participate in airway inflammation and in tissue destruction, and are involved in COPD, but the mechanisms need to be elucidated.
The Cystic Fibrosis Foundation has agreed to provide Prime Medicine Inc. an additional investment of up to $24 million to continue the development of a gene editing therapy for people with cystic fibrosis. Prime Medicine uses a gene editing technology called prime editing, which enables a wide range of modifications to the DNA with a high degree of precision.
Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterized by lung scarring, fibrosis and finally respiratory failure. Currently, few treatment options are available for IPF and they only slow down disease progression and do not reverse fibrosis. There is a need for new therapeutic targets that aid in the management of the disease.
Sino Biopharmaceutical Ltd. agreed to fully acquire Lanova Medicines Ltd. by buying an additional 95.09% stake in Lanova at a valuation of up to $950.92 million. Considering Lanova’s estimated cash and deposit of $450 million, Hong Kong-headquartered Sino agreed to pay $500.9 million to Lanova on the date of the transaction, set to close within 30 days of all conditions being satisfied, or July 31, 2025.
Synchrony Medical Ltd. received the greenlight from the U.S. FDA for its Libairty airway clearance system which is expected to transform the lives of people with chronic lung diseases. The company is now looking to raise $5 million in series A funding to support the launch of the product in the U.S. later this year.
Chiesi Farmaceutici SpA has identified new D-3-phosphoglycerate dehydrogenase (3-PGDH; PHGDH) inhibitors for the treatment of idiopathic pulmonary fibrosis.
RSS
